Semaglutide vs Tirzepatide: What the Research Shows

Semaglutide and tirzepatide are the two most-discussed peptide medications for weight management in 2026. Both are FDA-approved, both are weekly injections, and both have transformed clinical practice. But they are not the same drug — they have different mechanisms, different efficacy profiles, and different considerations for choice. This article compares what the published trials actually show.

Mechanism: Why Two Receptors Often Outperform One

Semaglutide is a GLP-1 receptor agonist. It binds only the GLP-1 receptor, mimicking the natural incretin hormone to enhance insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite.

Tirzepatide is a dual agonist: it binds both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. GIP is a second incretin hormone that, in combination with GLP-1 activity, appears to enhance the metabolic response in ways single-agonist therapy does not fully replicate.

Head-to-Head Efficacy: STEP vs SURMOUNT

Weight Reduction in Obesity (No Diabetes)

STEP 1 Trial (Semaglutide 2.4mg) — Wilding et al., NEJM 2021: In 1,961 adults with obesity, mean weight loss was 14.9% at 68 weeks versus 2.4% with placebo. 86% achieved ≥5% weight loss; 50% achieved ≥15%.

SURMOUNT-1 Trial (Tirzepatide) — Jastreboff et al., NEJM 2022: In 2,539 adults with obesity, mean weight losses were 15.0%, 19.5%, and 20.9% at doses of 5, 10, and 15mg respectively over 72 weeks. At 15mg, 57% achieved ≥20% body weight reduction — a threshold rarely seen with single-mechanism therapies.

In Patients With Type 2 Diabetes

SUSTAIN program (semaglutide): Strong glycemic outcomes, moderate weight loss (6-10% range typical in diabetes trials).

SURMOUNT-2 (tirzepatide in T2D + obesity): Mean weight losses of 13.4% (10mg) and 15.7% (15mg) in T2D patients — notably higher than historical diabetes trials with single GLP-1 agonists.

Direct Head-to-Head Data

SURPASS-2 compared tirzepatide to semaglutide 1mg (diabetes dose) in T2D patients. Tirzepatide at 5, 10, and 15mg produced greater HbA1c reduction and greater weight loss than semaglutide 1mg. Note that this trial used the diabetes-dose semaglutide (1mg), not the weight-management dose (2.4mg), limiting direct extrapolation.

Cardiovascular Outcomes

Semaglutide: The SELECT trial (2023) in 17,604 patients with obesity and established cardiovascular disease (no diabetes) demonstrated a 20% reduction in major adverse cardiovascular events (MACE). This is the only weight-management peptide with such cardiovascular outcome data to date.

Tirzepatide: A dedicated cardiovascular outcomes trial (SURPASS-CVOT) is ongoing. Interim safety analyses have not raised cardiovascular concerns, but long-term outcomes data are pending.

Side Effect Comparison

Both peptides share similar adverse effect profiles, predominantly GI:

• Nausea (30-50% during dose escalation)
• Diarrhea and constipation (10-25%)
• Vomiting (10-20%)
• Headache and fatigue (less common)
• Injection site reactions (uncommon)

Side effects typically peak during dose escalation and diminish over weeks. Structured titration (starting low, increasing gradually) is the standard approach to improve tolerability with both.

Serious adverse events are uncommon with either. Both carry boxed warnings for thyroid C-cell tumors (based on rodent data) and are contraindicated in patients with personal or family history of medullary thyroid cancer or MEN2.

Cost and Accessibility

Both Wegovy (semaglutide 2.4mg) and Zepbound (tirzepatide 15mg) have list prices exceeding $1,000 per month without insurance coverage. Compounded alternatives have been legally prescribed during FDA shortage periods, at often lower out-of-pocket cost. The compounded landscape is dynamic — speak with a licensed physician about current availability.

Who Might Choose Which?

This is a physician decision based on individual factors, but general considerations include:

• Semaglutide may be preferred for: Patients with established cardiovascular disease (due to SELECT data), patients who have tolerated it well, patients with certain insurance coverage.
• Tirzepatide may be preferred for: Patients who did not achieve target weight loss with semaglutide, patients with severe obesity where greater reduction is clinically important, patients with type 2 diabetes prioritizing aggressive glycemic control.

Neither is "better" universally — only "better for this patient, in this context."